• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The ONTT: Intravenous steroids lead to faster visual recovery in optic neuritis [Classics Series]

byCarl ShenandAndrew Cheung, MD MBA
June 30, 2017
in Emergency Classics, General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with first presentation of optic neuritis, treatment with intravenous methylprednisolone followed by oral prednisone resulted in faster visual recovery when compared to placebo, though only a small benefit persisted by 6 months.

2. The use of oral prednisone alone demonstrated no benefit in terms of visual recovery and appeared to increase the risk of recurrent episodes of optic neuritis compared to placebo.

Original Date of Publication: February 1992

Study Rundown: Optic neuritis is an inflammatory condition affecting the optic nerve and is most commonly associated with multiple sclerosis (MS). Clinically, it can present with a wide range of impairment in visual acuity, color vision, contrast sensitivity, and/or visual fields. In the 1990s, both ophthalmologists and neurologists were commonly using oral steroids to treat optic neuritis, though oral and intravenous steroid regimens had not yet been evaluated in a randomized controlled trial.

The Optic Neuritis Treatment Trial (ONTT) compared the effectiveness and safety of different steroid regimens in treating optic neuritis. The study found that intravenous methylprednisolone followed by oral prednisone hastened the rate of visual recovery in optic neuritis compared to placebo, with some improvement in vision noted at 6 months after treatment. Use of oral prednisone alone was shown to have no benefit compared to placebo, though it did lead to significantly higher rates of recurrent optic neuritis. Since the publication of the ONTT, subsequent studies have found that intravenous steroids do accelerate visual recovery in optic neuritis, though there were no differences in long-term visual outcomes.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: This open-label, randomized trial recruited patients between 18-46 years of age with acute unilateral optic neuritis with visual symptoms lasting ≤8 days, a relative afferent pupillary defect (RAPD), and visual field defect in the affected eye. Exclusion criteria included previous optic neuritis in the same eye or evidence of a systemic disease, other than MS, that could cause optic neuritis. A total of 457 patients were randomized to either i) intravenous methylprednisolone 250 mg q6h for 3 days followed by oral prednisone 1 mg/kg for 11 days, ii) oral prednisone 1 mg/kg for 14 days, or 3) placebo. Steroid treatment was followed by a short oral taper. Patients were followed for 24 months. The primary outcomes were visual fields and contrast sensitivity measured at 6 months.

RELATED REPORTS

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

Patients treated with methylprednisolone had a higher rate of return to normal vision in visual fields (p = 0.0001) and contrast sensitivity (p = 0.02), with a trend towards improved visual acuity (p = 0.09) compared to placebo. At 6 months, patients in the methylprednisolone group experienced better contrast sensitivity (p = 0.026) and color vision (p = 0.033), with no differences noted in visual acuity (p = 0.664). There were no significant differences in the rates of recovery for oral prednisone patients compared to placebo in all measures of vision (p > 0.05). By 24 months, 20 (13%) patients in the methylprednisolone group, 42 (27%) patients in the oral prednisone group, and 24 (15%) patients in the placebo group had experienced ≥1 new episode of optic neuritis. The oral prednisone group had a higher rate of new episodes of optic neuritis compared with placebo (RR 1.79, 95%CI 1.08-2.95).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: corticosteroidsonttoptic neuropathy
Previous Post

Benralizumab reduces oral steroid use in severe asthmatic patients

Next Post

Cardiovascular testing after emergency department presentation may not reduce risk of myocardial infarction

RelatedReports

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease
StudyGraphics

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

January 6, 2022
#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation
StudyGraphics

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

December 23, 2021
Adalimumab aids in control of noninfectious uveitis
Infectious Disease

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

October 26, 2021
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;

June 24, 2021
Next Post
Variability in out-of-hospital pediatric cardiac arrest outcomes

Cardiovascular testing after emergency department presentation may not reduce risk of myocardial infarction

Smoking during pregnancy associated with aerobic fitness of children

E-cigarette use linked to increased risk of cigarette smoking in adolescents and young adults

Tonsillectomy may have short-term benefits in recurrent throat infection

Low risk allergy symptoms not linked to true penicillin allergy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.